Epitalon vs Vilon.

Epitalon (also spelled Epithalon or Epithalone; sequence Ala-Glu-Asp-Gly, abbreviated AEDG) is a synthetic tetrapeptide developed in the 1980s by the Russian gerontologist Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. It was designed to reproduce the proposed active fragment of Epithalamin, a crude peptide extract of the bovine pineal gland, and is classified as a short "peptide bioregulator." It is not a small-molecule drug or a hormone; the corresponding AEDG sequence was reported to be detectable in physiological pineal tissue only in 2017.

Vilon is a synthetic dipeptide, L-lysyl-L-glutamate (Lys-Glu), one of the short peptide bioregulators developed by Vladimir Khavinson's St. Petersburg Institute of Bioregulation and Gerontology in Russia. It was designed as a minimal synthetic analogue reflecting active sequences found in thymic peptide preparations such as thymalin. Despite its very small size, it is promoted as a geroprotective and immunomodulatory agent. It is a research compound with no approved medical use.

The most cited proposed mechanism is activation of telomerase: in cultured human somatic cells, Epitalon has been reported to induce telomerase reverse transcriptase expression, lengthen telomeres, and extend the number of cell divisions past normal replicative (Hayflick) limits. A second proposed mechanism is epigenetic/gene-regulatory: AEDG is a short, cell-penetrating peptide that is hypothesized to bind directly to specific DNA promoter regions and modulate transcription, with reported effects on melatonin-synthesis enzymes (e.g., AANAT), interleukin-2, and neuronal differentiation genes. It has also been described as modulating pineal melatonin output and as having antioxidant effects in animal and Drosophila models. Importantly, after roughly 25 years of research the authoritative 2025 review concludes the true mechanism of action remains unclear, and some findings (e.g., on melatonin secretion) directly conflict between studies.

Vilon is hypothesized to act as a gene-regulating bioregulator: proponents propose that the dipeptide can penetrate cells, bind DNA and histones, and alter chromatin accessibility to switch on genes silenced with aging. In immune tissue it is reported to activate T-helper cells and modulate age-associated immune changes. Some microarray studies from the originating group describe changes in gene expression in mouse tissues after vilon exposure. As with other Khavinson peptides, these mechanistic claims rest mainly on the developing laboratory's own experiments rather than on independent confirmation.

Most evidence is preclinical (cell culture, Drosophila, mice, and rats), where Epitalon and Epithalamin have shown telomere lengthening and antioxidant effects; in some rodent lifespan experiments from Khavinson's group, they also reduced tumor incidence and extended mean lifespan. Human data are far thinner and come almost entirely from the same Russian research network. The most-cited human report (Khavinson & Morozov, Neuro Endocrinol Lett 2003, PMID 14523363) describes a 6–8 year follow-up of 266 elderly subjects in which Epithalamin (the pineal extract, not synthetic Epitalon) and thymalin were associated with reduced mortality versus controls; a related 15-year follow-up was published in 2011 (PMID 22451889). There are also small open-label reports in retinitis pigmentosa and a circadian/melatonin study. These studies are open-label, often unblinded, frequently use the crude extract rather than the synthetic tetrapeptide, and have not been independently replicated by Western randomized controlled trials. The human-vs-preclinical gap is large and unresolved.

The vilon evidence base is almost entirely preclinical and comes from Vladimir Khavinson, Vladimir Anisimov and colleagues, published largely in Russian journals. Reported findings include inhibition of spontaneous and chemically induced tumors and increased lifespan in mice, plus effects on biological-age markers and gene expression. These are animal and cell studies from a single research tradition; there are essentially no independent Western randomized controlled trials or robust human efficacy data. To state it plainly: there are no human clinical trials of vilon in the mainstream indexed literature, so every claim about human benefit is an extrapolation from rodent and cell-culture work. The animal studies are typically conducted in inbred mouse strains at a single institution, with lifespan and tumor incidence as endpoints, without blinded pathology review, without preregistration, and without replication in a second laboratory using a different animal facility and diet, all of which are known to influence rodent lifespan results. The mechanistic work is similar in character: microarray and cell-culture studies attributing changes in gene expression to direct dipeptide interaction with DNA and histones, reported by the originating group and by a small number of collaborating laboratories, including studies of short peptides in stem cell differentiation and in monocyte and macrophage cell lines. The internal consistency of results within the group is notable, but the lack of external replication is a major limitation. Claims of anti-aging or immune benefit in humans should therefore be regarded as unproven. Compared with its siblings in the same Khavinson tradition, vilon sits at the least developed end: thymalin and cortexin at least have registered clinical use and observational human reports in Russia, and Cerebrolysin, an unrelated animal-tissue peptide preparation, has enough independent randomized trials to have been assessed twice by Cochrane. Vilon has none of that. There is no published modern toxicology dossier, no human pharmacokinetic data, and no regulatory dossier available for external review.

No rigorous, modern toxicology package exists for Epitalon. The 2025 International Journal of Molecular Sciences review explicitly states that data on this peptide's short- and long-term toxicity, genotoxicity, carcinogenic potential, and drug interactions are missing, and that these would be required before it could be approved as a pharmaceutical ingredient outside Russia. A specific theoretical concern is that a telomerase-activating compound could in principle promote survival or proliferation of abnormal cells, so its long-term oncologic safety in humans is genuinely unknown. Material sold for "research" use is unregulated, with no assurance of identity, purity, sterility, or endotoxin control. There are essentially no controlled human safety trials by Western standards.

In the animal studies reported by its developers, vilon appears to be well tolerated at the doses tested, with low toxicity described. However, there is no meaningful independent human safety data, no long-term human studies, and no regulatory safety review outside its originating context. Because no human trial has been conducted, there is no adverse-event table to consult: statements that vilon is safe in people are assertions rather than findings. The absence of a published modern toxicology package is the specific gap that matters, since a regulator would expect repeat-dose toxicity in two species, genotoxicity testing, reproductive toxicity, local tolerance at the injection site, and immunogenicity assessment before any first-in-human study. None of that is available in the indexed literature. The identity and purity of material sold as vilon for research use are not guaranteed, and lyophilized vials distributed through research-chemical channels are not manufactured to pharmaceutical standards, are not tested for sterility or bacterial endotoxin, and may differ from the labeled peptide in content or purity. Injecting a non-sterile preparation carries the ordinary hazards of contamination, including local infection and systemic febrile reactions. A compound proposed to alter gene expression and immune cell behavior also warrants caution in anyone with a history of malignancy or autoimmune disease, a question that has never been addressed experimentally in humans. This is educational information only and not medical or dosing advice.

Epitalon/Epithalamin reached clinical use only in Russia and has never been approved by the FDA or EMA; it is not an approved drug or dietary supplement in the United States and is sold there only as a research-use-only chemical. It is not a WADA-prohibited substance by name, though peptide-based agents can fall under broader anti-doping categories.

Vilon is not approved as a drug by the US FDA, the European Medicines Agency, or other major Western regulators, and it is not a dietary supplement. It is sold and used only as a research chemical, and human clinical use is not sanctioned in the US.